Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer

Molecular Endocrinology

Volumn 17, Issue 4, 2003, Pages 575-588

  Cui, Xiaojiang ^a   Zhang, Ping ^a   Deng, Wanleng ^a   Oesterreich, Steffi ^a   Lu , Yiling ^b   Mills, Gordon B ^b   Lee, Adrian V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; GESTAGEN; LIGAND; MESSENGER RNA; MIFEPRISTONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROMEGESTONE; PROTEASOME; PROTEIN INHIBITOR; RAPAMYCIN; SOMATOMEDIN C;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CYCLIN D1; ENZYME INHIBITORS; FEMALE; GROWTH SUBSTANCES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PREDICTIVE VALUE OF TESTS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 0037385522     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0318     Document Type: Article

References (59)

1. LeRoith D 1996 Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab 10:49-73
2. Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA, Surmacz E 1997 Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer 72:828-834
3. Baserga R 1995 The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249-252
4. Baserga R 1996 Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 14:150-152
5. Huynh H, Alpert L, Pollak M 1996 Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Cancer Res 56:3651-3654
6. Ruan W, Kleinberg DL 1999 Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140:5075-5081
7. Lee AV, Yee D 1995 Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415-421
8. Karey KP, Sirbasku DA 1988 Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res 48:4083-4092
9. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr FC, Allred DC, Osborne CK 1989 Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423
10. Yee D 1994 The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32:85-95
11. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
12. Lee AV, Hilsenbeck SG, Yee D 1998 IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 47:295-302
13. McGuire WL 1978 Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428-433
14. Clarke CL, Sutherland RL 1990 Progestin regulation of cellular proliferation. Endocr Rev 11:266-301
15. Graham JD, Clarke CL 1997 Physiological action of progesterone in target tissues. Endocr Rev 18:502-519
16. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery Jr CA, Shyamala G, Conneely OM, O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266-2278
17. Horwitz KB 1992 The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146-163
18. Kaneko KJ, Gelinas C, Gorski J 1993 Activation of the silent progesterone receptor gene by ectopic expression of estrogen receptors in a rat fibroblast cell line. Biochemistry 32:8348-8359
19. Horwitz, KB, Mockus MB, Lessey BA 1982 Variant T47D human breast cancer cells with high progesterone receptor levels despite estrogen and antiestrogen resistance. Cell 28:633-642
20. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
21. Musgrove EA, Lee CS, Sutherland RL 1991 Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11:5032-5043
22. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB 1997 Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11:1593-1607
23. Lin VC, Ng EH, Aw SE, Tan MG, Ng EH, Chan VS, Ho GH 1999 Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 5:395-403
24. Lange CA, Richer JK, Shen T, Kathryn B 1998 Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273:31308-31316
25. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB 1998 Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273:31317-31326
26. Lapidus RG, Nass SJ, Davidson NE 1998 The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3:85-94
27. Balleine RL, Earl MJ, Greenberg ML, Clarke CL 1999 Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 79:1564-1571
28. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T 2000 Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 54:32-37
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin W J, Stuart SG, Udove J, Ullrich A, Press MF 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
30. Harari D, Yarden Y 2000 Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19:6102-6114
31. Dupont J, Le Roith D 2001 Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 54:149-154
32. Lange CA, Shen T, Horwitz KB Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
33. Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D 2000 Insulin-like growth factor I-induced degradation of insulin receptor substrate I is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol Cell Biol 20:1489-1496
34. Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features. Int J Cancer 59:351-356
35. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV 2001 Re-expression of estrogen receptor @ in estrogen receptor α-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 61:5771-5777
36. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT 2000 A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504-3513
37. Clayton SJ, May FE, Westley BR 1997 Insulin-like growth factors control the regulation of oestrogen and progesterone receptor expression by oestrogens. Mol Cell Endocrinot 128:57-68
38. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB 2000 Role of insulin-like growth factor-I in regulating estrogen receptor-α gene expression. J Cell Biochem 76:605-614
39. Aronica SM, Katzenellenbogen BS 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743-752
40. Lee AV, Weng CN, Jackson JG, Yee D 1997 Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152:39-47
41. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP, Korach KS 2002 Requirement of estrogen receptor-α in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 277:8531-8537
42. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price Jr RH, Pestell RG, Kushner PJ 2002 Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J Biol Chem 277:24353-24360
43. Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH 2002 Synergistic proliferative action of insulin-like growth factor I and 17 β-estradiol in MCF-7S breast tumor cells. Exp Cell Res 273:107-117
44. Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH 2000 Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. J Endocrinol 166:329-338
45. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A 2000 A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-4511
46. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
47. Potapova O, Fakhrai H, Mercola D Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism Int J Cancer 66:669-677
48. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID, Belfiore A 1992 Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52:3924-3930
49. Flier JS, Usher P, Moses AC 1986 Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci USA 83:664-668
50. Cho H, Aronica SM, Katzenellenbogen BS 1994 Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 134:658-664
51. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788
52. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA 2002 Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 245:42-56
53. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I 2001 HER-2 amplification impedes the antiproliferative effectsol hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458
54. Shen T, Horwitz KB, Lange CA 2001 Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21:6122-6131
55. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J 1996 Activation of phospho-inositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442-2451
56. Patel S, Lochhead PA, Rena G, Fumagalli S, Pende M, Kozma SC, Thomas G, Sutherland C 2002 Insulin reguiation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of rapamycin, but independent of ribosomal S6 kinase activity. J Biol Chem 277:9889-9895
57. Osborne CK, Hobbs K, Trent JM 1987 Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 9:111-121
58. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN 1995 The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736
59. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209-5218